Since 2014, the FDA has approved use of PARP inhibitors for treatment of ovarian cancer in various clinical contexts including as monotherapy for recurrent ovarian cancer, as maintenance therapy after response to platinum-based chemotherapy in recurrent ovarian cancer, and as maintenance therapy after response to upfront platinum-based chemotherapy. However, in 2022, the FDA sent out a series of “Dear Healthcare Provider” letters and, consequently, many of the previously approved indications were withdrawn. Tune into the latest installment of SGO Journal Club where our panelists will review updated survival data, the dramatically changed landscape of approved indications, and MDS/AML risk with PARP inhibitor therapy.